Hodgkin Lymphoma Patient Survey: Experience with Brentuximab-vedotin (Adcetris)

Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression

New Targeted Therapy Safe and Effective in Refractory Non-Hodgkin’s Lymphoma Patients

New Targeted Therapy Safe and Effective in Refractory Non-Hodgkin’s Lymphoma Patients

Manitoba Leads the Way in CLL Research and Treatment

Hodgkin Lymphoma Patient, Survivor & Caregiver Surveys

CAR-T Cell Therapy Shows Promise in Aggressive NHL